103 results about "Erlotinib Hydrochloride" patented technology

The invention provides a preparation method of erlotinib hydrochloride. The method comprises the following steps: taking 6,7-dimethoxy-3,4-dihydro-quinazoline as an initial raw material, chlorinating directly, then reacting with 3-aminophenylacetylene, afterwards removing methyl on the positions of 6 and 7 and finally introducing a methoxyethyl side chain to generate the erlotinib hydrochloride. The invention has the technological lines of mild reaction condition, no need of high temperature, deep cooling, energy saving and environment friendliness; the whole line has better yield and quality; and the reaction steps are little, the reaction is stable and controllable, the postprocessing is very simple and convenient, and the industrialized production is easy.

Erlotinib hydrochloride hydrate is formed from an aqueous solution and is useful as a pharmaceutical and as a purification intermediate.

The invention relates to a process of a chemical synthesis medicament, in particular to a novel synthesis process of erlotinib hydrochloride serving as an antitumor medicament, and a novel intermediate. The process has the advantages of low-price and readily-available raw materials, mild conditions in a reacting process, no device with special requirements and suitability for industrial production.

The present invention discloses an improved and novel process for the preparation of erlotinib (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine) of formula (1), which comprises: (i) demethylation of commercially available 6,7-dimethoxy-4(3H)-quinazolinone of formula (8); acetylation using acetic anhydride; (iii) introduction of a leaving group at C-4 position in quinazolinone; (iv) condensation with 3-ethynylaniline to get novel compound of formula (12); (v) deacetylation to get novel dihydroxy compound of formula (13); and (vi) O-alkylation with 2-iodoethylmethyl ether to get the erlotinib base of formula (1). Erlotinib base is purified by recrystallization from ethyl acetate to get a HPLC purity of >99.5%. Salt formation of this base with hydrogen chloride gave pharmaceutically acceptable erlotinib hydrochloride of formula (1a) with a HPLC purity of >99.8%. Erlotinib hydrochloride is useful for the treatment of proliferative disorders, such as cancers, in humans.

The invention provides an application of a compound containing tyrosine kinase inhibitor and resveratrol in preparing antitumor drugs. The application is characterized in that the tyrosine kinase inhibitor is selected from one of imatinib, gefitinib, erlotinib hydrochloride tablets, sorafenib, dasatinib tablets and tasigna or pharmaceutically acceptable salts or solvates or pharmaceutically acceptable salt solvents thereof; the tumor is selected from one of gastric cancer, liver cancer, lung cancer, kidney cancer, cervical cancer, pancreatic cancer, breast cancer, esophagus cancer, nasopharynxcancer and ovarian cancer; the mole ratio of resveratrol to tyrosine kinase inhibitor is (1-100):1.

The invention discloses a preparation method of an erlotinib hydrochloride key intermediate 4-chloro-6,7-di(2-methoxyethoxy)quinazoline, which comprises the following steps: reacting the raw material ethyl 3,4-dihydroxybenzoate with ethyl 2-methoxysulfonate, nitrating, reducing, cyclizing and chlorinating to obtain the key intermediate 4-chloro-6,7-di(2-methoxyethoxy)quinazoline. The method has the advantages of mild reaction conditions, low cost, high purity and high total yield (up to 74.8%), and can easily implement industrial production.

The invention provides a preparation method of Erlotinib hydrochloride with the crystal form A. The method comprises the following steps: mixing Erlotinib free alkali with organic solvent, and then dropping the hydrochloric acid solution of ester to obtain the Erlotinib hydrochloride with the crystal form A.

The invention discloses an anti-cancer drug erlotinib hydrochloride tablet and a preparation method thereof. A preparation of the drug is prepared from raw materials and auxiliary materials. The auxiliary materials contain polacrilin potassium and mesoporous silicon dioxide. The preparation method comprises the following steps: (1) dissolving a binder in an acidic solution, adding erlotinib hydrochloride into the acidic solution, stirring and grinding for standby application; (2) measuring the polacrilin potassium, mesoporous silicon dioxide and a diluting agent, uniformly mixing in a fluidized bed, then spraying a mixed solution obtained in the step (1), granulating, drying, and size stabilizing; (3) uniformly mixing dry particles and a lubricating agent, and tabletting. The preparation has the advantages of fast dissolution, good dissolution stability and simple preparation process.

The invention provides a medicine composition containing erlotinib hydrochloride. The medicine composition has the advantages of being good in digestion performance, high in stability, low in clinical pharmacy risk and the like. In the production and preparation process, raw materials and auxiliary materials do not need to be specially treated, and the production process is simple.

The invention relates to a synthesis method of erlotinib hydrochloride, which comprises the following technological process of: a, synthesizing m-nitrocinnamic acid by taking m-nitrobenzaldehyde as raw material; b, carrying out bromine addition to obtain 2, 3-dibromo-3-(3'-nitrophenyl) propanoic acid; c, carrying out decarboxylation and dehydrobromination to obtain (Z)-beta-bromo-(3'-nitrophenyl) ethylene; d, enabling the (Z)-beta-bromo-(3'-nitrophenyl) ethylene to have reaction with metal hydride to obtain m-nitrobenzene acetylene; e, reducing to obtain m-aminophenyl acetylene; and f, enabling the m-aminophenyl acetylene to have reaction with 4-chloro-6, 7-bi-(2-methoxy-ethoxy)-quinazoline, to obtain the erlotinib hydrochloride. The raw materials of the synthesis method are easy to obtain and low in cost, and the synthesis method is mild in reaction conditions, simple and convenient in operation, higher in yield and suitable for amplification.

The present invention provides an improved and commercially viable process for preparation of erlotinib substantially free of N-methoxyethyl impurity, namely N-[(3-ethynylphenyl)-(2-methoxyethyl)]-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, and its pharmaceutically acceptable acid addition salts thereof in High purity and in high yield. According to the present invention, erlotinib or a pharmaceutically acceptable acid addition salt of erlotinib substantially free of N-methoxyethyl impurity is prepared by isolating erlotinib or a pharmaceutically acceptable salt of erlotinib from a solvent medium comprising dimethyl sulfoxide and an alcoholic solvent.

The present invention discloses an improved and efficient process for preparing Erlotinib hydrochloride suitable as a cancer drug.

The present invention relates to a preparation method for an erlotinib hydrochloride impurity N-(3-vinyl-phenyl)--quinolineamine hydrochloride. Firstly, 6,7-bis-(2-methoxyethoxy)-4(3H)-quinazolinone reacts with an acylating reagent to obtain 4-chloro-6,7-bis-(2-methoxyethoxy)-quinazoline, then the 4-chloro-6,7-bis-(2-methoxyethoxy)-quinazoline reacts with m-aminostyrene to generate the target product N-(3-vinyl-phenyl)--quinolineamine hydrochloride. The present method has characteristics of a short synthetic route, simple operation and high product purity up to 99.77%, and provides conditions for the qualitative and quantitative analysis of impurity in the production of erlotinib hydrochloride, thereby further improving the quality standards of erlotinib hydrochloride and providing guidance for safe medication of people.

The invention specifically relates to a preparation method of an erlotinib hydrochloride crystal form A. The preparation method comprises the following steps of: mixing erlotinib hydrochloride free alkaline monomer with an organic solvent; and dropwise adding a non-ether hydrogen chloride solution or a hydrogen chloride solution for reacting to obtain the erlotinib hydrochloride crystal form A under low-temperature reaction condition. The preparation method of the erlotinib hydrochloride crystal form A is incapable of affecting industrial production due to weather temperature changes, simple and convenient to operate, very good in safety, high in stability, good in repeatability and more suitable for the industrial production of the erlotinib hydrochloride.

The invention discloses an erlotinib hydrochloride pharmaceutical composition without containing a surfactant. The erlotinib hydrochloride pharmaceutical composition comprises the following components in parts by weight: 150-300 parts of erlotinib hydrochloride, 40-250 parts of diluents, 80-190 parts of disintegrants and 5-10 parts of lubricants. The invention also provides a preparation method of the pharmaceutical composition. Use of a special auxiliary material of sodium dodecyl sulfate in the composition is rejected, the problem that in vitro dissolution reaches a dissolution platform under special determination conditions is solved simultaneously, the erlotinib hydrochloride pharmaceutical composition is consistent with a reference preparation, in vivo bioavailability is not affected, and the safety of a product in clinical use is improved.

The invention relates to a novel preparation method of hydrochloric acid erlotinib crystal form F. The method comprises steps that erlotinib free alkali in C4 alcohol is added into hydrogen chloride dissolved in an organic solvent, and the formed hydrochloric acid erlotinib is crystallized. The method has the advantages of suitability for mass production and good reproducibility. Furthermore, the invention also comprises a method of converting hydrochloric acid erlotinib crystal form F into other forms.

The invention discloses an erlotinib hydrochloride composition tablet and a preparation method thereof. The erlotinib hydrochloride composition tablet comprises the following ingredients in percentage by weight: 20-38% of erlotinib hydrochloride crystals, 30-50% of pregelatinized starch, 25-45% of calcium sulfate, 1-5% of ethyl cellulose, 6-12% of beta-cyclodextrin, 0.2-3% of Tween, 5-10% of crosslinked sodium carboxymethyl starch, 0.5-1.5% of sodium stearyl fumarate and 0.2-2% of micropowder silica gel. A preparation process route of the erlotinib hydrochloride composition tablet is stable, simple and easy to operate, set technological parameters can effectively control each reaction, and sample detection results show that an erlotinib hydrochloride crude drug is stable in crystal form and relatively good in purity and quality requirements of a final product can be met. A synthesis and production technology of the erlotinib hydrochloride composition tablet is simple, stable and feasible and is applicable to mass production; and quality is controllable, and stability is relatively good.

The invention relates to a preparation method of important impurities in an erlotinib hydrochloride raw material or preparation technology. Compounds with formulas II to V are erlotinib hydrochloride impurities, and can be used as impurity reference substances to control the purity of theerlotinib hydrochloride raw material or the preparation.

An industrialized production method for erlotinib hydrochloride B type crystal comprises: reacting a raw material erlotinib with hydrogen chloride, and after the reaction cooling and precipitating a crystal to obtain the finished product erlotinib hydrochloride B type crystal, wherein the reaction solvent is acetone or a mixture of acetone and water. The usable raw materials of the method comprise erlotinib amorphous solid or crystal, wherein the crystal form of the crystal is unlimited and can be a singular crystal form or a mixed crystal form. The method is simple, has no crystal form conversion step, is applicable to industrialized production, and has no toxic and harmful solvents needed and no pollution to environment; and product purity reaches 99% or more and product yield reaches 95% or more.

The invention belongs to the technical field of pharmaceutical chemicals, and in particular relates to a preparation method of an erlotinib base monohydrate crystal form I. The preparation method comprises the following steps: stirring and mixing erlotinib hydrochloride, base and an organic solvent, or stirring and mixing erlotinib base and an organic solvent; dropwise adding a solution system after an reaction or after being classified to water under a stirring condition; while stirring, decreasing temperature to 0-5 DEG; and filtering and drying in a vacuum environment to obtain erlotinib base monohydrate crystal form I. The erlotinib base monohydrate crystal form I is prepared by crystallization at room temperature through an organic solvent which is cheap, easy to prepare, green and environment-friendly; and the preparation method is safe and environment-friendly in process route, simple to operate, low in cost, good in repeatability, stable, applicable to industrial production and quite high in economic value. The prepared erlotinib base disclosed by the invention has high purity, and can be used for preparing erlotinib hydrochloride high in purity.

The invention relates to an erlotinib (Erlotinib Hydrochloride) sustained-release preparation for treating the non-small cell lung cancer. The erlotinib sustained-release preparation is prepared fromthe following raw and auxiliary materials in percentage: 30% to 50% of erlotinib, 10% to 40% of sustained-release material, 30% to 50% of filler, 1% to 10% of solubilizer and 1% to 4% of lubricant. The invention further provides a preparation method of the sustained-release tablets. The preparation method comprises the steps of: firstly, placing the erlotinib, the sustained-release material and the filler into a high-efficiency wet granulator to uniformly mix; then adding the solubilizer into purified water to prepare solution; adding a proper volume of solution into a pot to carry out wet granulation; after particles are dried, adding a proper volume of lubricant; and after uniformly mixing, carrying out tabletting to form the tablets. Compared to a common drug, the erlotinib sustained-release preparation has the advantages of reducing the "peak valley" effect of in-vivo release of the drug, reducing a probability that cancer cells generate drug resistance, reducing adverse reactionson a patient, which are generated due to excessively high blood concentration of the drug, enabling the blood concentration to be continuously and stably kept to optimal treatment concentration, improving bioavailability of the drug, reinforcing the curative effect and improving administration safety.